ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Abbreviated Vaccine Treatment May Be an Effective Alternative to Three to Five Years of Allergy Shots

by Alice Goodman • January 1, 2007

  • Tweet
  • Email
Print-Friendly Version

A regimen of six weekly shots of a novel vaccine may be an effective long-term approach for patients with allergic rhinitis, sparing them injections once or twice a week for three to five years, according to results of a pilot study published recently in the New England Journal of Medicine. The treatment, Amb 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC), combines a ragweed-pollen antigen (Amb a 1) that sets off the allergic reaction with a synthetic bit of DNA (phosphorothiotate oligodeoxyribonucelotide immunostimulatory sequence) that stimulates the immune system.

You Might Also Like

No related posts.

Explore This Issue
January 2007

“This pilot study suggests that the clinical effects of AIC appear to be associated with the mechanism of long-lasting immune modulation…. This approach may also be applicable to other substances that lead to allergic reactions,” according to lead author of the study, Peter S. Creticos, MD, who is Associate Professor of Medicine in the Department of Medicine, Division of Allergy and Clinical Immunology, at the Johns Hopkins University School of Medicine in Baltimore.

The randomized, double-blind, placebo-controlled Phase II trial included 25 adults with documented seasonal (fall) allergies to ragweed, 17 of whom completed the trial. Patients were 23 to 60 years old. All patients received six weekly injections before the onset of the first ragweed season and then were monitored during the next two ragweed seasons. AIC was prepared by the same company (Dynavax) and the same lot of standardized ragweed was used throughout the study. No additional injections were given, but patients were allowed to use medications to relieve eye and nasal symptoms that were difficult to tolerate.

AIC had no effect on the primary endpoint—vascular permeability response as measured by level of albumin, a marker of vascular leakage and inflammation that is reduced by standard allergen immunotherapy. However, AIC achieved impressive improvements in symptoms. During the first ragweed season, the group that received the AIC vaccine had improved peak-season rhinitis scores on the visual analog scale, peak-season daily nasal symptom diary scores, and midseason overall quality of life scores compared with the placebo group. A transient increase in Amb a 1-specific IgG antibody was observed in the AIC-treated group, along with a suppression of the seasonal increase in Amb a 1-specific IgE antibody. A reduction in the number of interleukin-4-positive basophils in patients who received the novel vaccine was correlated with lower rhinitis visual analog scores. In the second ragweed season, the clinical benefits of AIC were seen again, and the seasonal specific IgE antibody response was suppressed again, with no significant change in IgE antibody titer during the ragweed season. The novel vaccine appeared to be safe and well-tolerated. No pattern of vaccine-associated systemic reactions or clinically significant laboratory abnormalities was observed.

Pages: 1 2 3 | Single Page

Filed Under: Articles, Clinical, Features Issue: January 2007

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Complications for When Physicians Change a Maiden Name
    • Vertigo in the Elderly: What Does It Mean?
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • How To: A Modified Endoscopic Draf III Approach for Dermoid Cysts
    • How To: Inferior Meatus Augmentation Procedure for Empty Nose Syndrome
    • Otolaryngology Resident Says Art Helps Her Process Ideas on Wellness, Burnout
    • Age-Related Hearing Loss Is Associated with Incident Dementia in Adults Over 60
    • COVID-19 Associated with Upsurge in Otolaryngology Publications

Polls

Do you report near-miss or no-harm events to your patients?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939